Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.68 USD | -0.55% | -10.80% | +28.41% |
May. 13 | Avalo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 12.08M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | -36M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-12.8
x | P/E ratio 2025 * |
-12
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
1 day | -0.55% | ||
1 week | -10.80% | ||
1 month | -31.75% | ||
3 months | +164.97% | ||
6 months | -30.35% | ||
Current year | +28.41% |
Managers | Title | Age | Since |
---|---|---|---|
Garry Neil
CEO | Chief Executive Officer | 70 | 20-01-31 |
Director of Finance/CFO | 40 | 17-12-31 | |
Dino Miano
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
June Almenoff
BRD | Director/Board Member | 67 | 21-11-09 |
Gilla Kaplan
BRD | Director/Board Member | 76 | 20-10-11 |
Garry Neil
CEO | Chief Executive Officer | 70 | 20-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 11.68 | -0.55% | 12,696 |
24-05-30 | 11.75 | -2.73% | 8,617 |
24-05-29 | 12.08 | +4.95% | 14,610 |
24-05-28 | 11.51 | -12.14% | 16,107 |
24-05-24 | 13.1 | +17.49% | 44,830 |
Delayed Quote Nasdaq, May 31, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.41% | 12.08M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- AVTX Stock